Predictive mathematical modelling of recurrence periods for the secondary distant metastases in patients with ER/PR/HER2/Ki-67 subtypes of breast cancer

Predictive mathematical modelling of recurrence periods for the secondary distant metastases in patients with ER/PR/HER2/Ki-67 subtypes of breast cancer

Bibliographic Details
Main Authors:	E. Tyuryumina, A. Neznanov, J. Turumin
Format:	Article
Language:	English
Published:	Elsevier 2021-04-01
Series:	Breast
Online Access:	http://www.sciencedirect.com/science/article/pii/S096097762100196X

Similar Items

A Mathematical Model to Predict Diagnostic Periods for Secondary Distant Metastases in Patients with ER/PR/HER2/Ki-67 Subtypes of Breast Cancer
by: Ella Ya. Tyuryumina, et al.
Published: (2020-08-01)

Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain
by: Chen Jiaxin, et al.
Published: (2022-10-01)

A study on molecular subtype of breast carcinoma using ER, HER2, PR, and its relation with Ki67
by: Haricharan BV, et al.
Published: (2023-11-01)

ER, PR, HER2, Ki-67 and CK5 in Early and Late Relapsing Breast Cancer—Reduced CK5 Expression in Metastases
by: Kristiina Joensuu, et al.
Published: (2013-01-01)

ER, PR, HER2, Ki-67 and CK5 in Early and Late Relapsing Breast Cancer—Reduced CK5 Expression in Metastases
by: Kristiina Joensuu, et al.
Published: (2013-02-01)

An Advanced Automated Image Analysis Model for Scoring of ER, PR, HER-2 and Ki-67 in Breast Carcinoma
by: Min Feng, et al.
Published: (2021-01-01)

Expression changes of ER, PR, HER2, and Ki-67 in primary and metastatic breast cancer and its clinical significance
by: Xueyang Hu, et al.
Published: (2023-04-01)

Immunohistochemical Survey of Invasive Ductal Carcinoma of the Breast, using ER, PR, HER2 and KI-67 biomarkers, in Uyo, Nigeria
by: Eziagu UB, et al.
Published: (2022-09-01)

PIK3CA, KI67, Estrogen (ER) and Progesterone Receptors (PR) Expression Pattern of in HER2 Positive Breast Cancers
by: Samuel I. Ogenyi, et al.
Published: (2022-02-01)

<i>f</i>HER2, PR, ER, Ki-67 and Cytokeratin 5/6 Expression in Benign Feline Mammary Lesions
by: Maria Soares, et al.
Published: (2022-06-01)

P041 Evaluation of an optimal cut point for the Ki-67 as a predictive recurrent marker of early-stage ER/PR positive and HER2 negative breast cancer
by: P. Ruangprasertkun, et al.
Published: (2023-03-01)

Expression and significance of Her2 and Ki-67 in gastric adenocarcinoma without distant metastasis: a cohort study
by: Zhijian Wei, et al.
Published: (2020-10-01)

The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines
by: Kristina Subik, et al.
Published: (2010-01-01)

Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
by: Luca Gianni, et al.
Published: (2022-01-01)

دور التلوينات المناعية النسيجية الهرمونيةER) ,PR Her2/neu,) و Ki-67)) في التصنيف الجزيئي لسرطان الثدي وعلاقتها بالإنذار
by: عيسى أحمد, et al.
Published: (2019-11-01)

دور التلوينات المناعية النسيجية الهرمونيةER) ,PR Her2/neu,) و Ki-67)) في التصنيف الجزيئي لسرطان الثدي وعلاقتها بالإنذار
by: عيسى أحمد, et al.
Published: (2019-11-01)

Hubungan antara overekspresi Vascular Endothelial Growth Factor dengan Er, Pr, Her-2, Ki67 pada subtipe molekular karsinoma payudara invasif tidak spesifik
by: Ellyzar Ellyzar, et al.
Published: (2017-01-01)

The Er/Ki-67 Proportion in Breast Tumours - An Immunohistochemical Study
by: Rachna, et al.
Published: (2016-04-01)

Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis
by: Tashima Rumiko, et al.
Published: (2011-10-01)

Breast Cancer Subtypes among Iraqi Patients: Identified By Their ER, PR and HER2 Status
by: Nada A.S. Alwan, et al.
Published: (2018-01-01)

Possible Association of CD68 Positive Macrophages with Some other Prognostic Factors (ki67, ER, PR, Her2 neu) in Primary Breast Cancer and Axillary Lymph Node Metastasis
by: Hakime Khalili, et al.
Published: (2017-11-01)

Correlation of p53 and KI-67 expression with grade and subtype of ependymoma
by: Lakshmi P Manasa, et al.
Published: (2012-01-01)

Protein co-expression networks identified from HOT lesions of ER+HER2–Ki-67high luminal breast carcinomas
by: Kimito Yamada, et al.
Published: (2021-01-01)

Comprehensive Assessment of ERα, PR, Ki67, P53 to Predict the Risk of Lymph Node Metastasis in Low-Risk Endometrial Cancer
by: Yuzhen Huang, et al.
Published: (2023-12-01)

The prognostic role of Ki67, p53, Her2, and CyD1 immunohistochemical markers in recurrent parasagittal meningiomas
by: Andrii H. Sirko, et al.
Published: (2023-06-01)

Lokal ileri evre meme kanserli hastalarda neoadjuvan kemoterapinin ER, PR, c-erb2, VEGF ve Ki-67 üzerine etkisi
by: Ahmet Gökhan SARITAŞ, et al.
Published: (2019-03-01)

External quality assessment (EQA) program for the immunohistochemical detection of ER, PR and Ki-67 in breast cancer: results of an interlaboratory reproducibility ring study in China
by: Tianjie Pu, et al.
Published: (2019-10-01)

AI‐based intra‐tumor heterogeneity score of Ki67 expression as a prognostic marker for early‐stage ER+/HER2− breast cancer
by: Wenqi Lu, et al.
Published: (2024-01-01)

MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers
by: Dorsay Sadeghian, et al.
Published: (2022-02-01)

Ki67 index in intrinsic breast cancer subtypes and its association with prognostic parameters
by: Atif Ali Hashmi, et al.
Published: (2019-09-01)

Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer
by: Parise Carol, et al.
Published: (2010-05-01)

RETRACTED: Correlation between ER, PR, P53, Ki67 expression, and high-risk HPV infection in patients with different levels of cervical intraepithelial neoplasia
by: Gao Yuan
Published: (2020-07-01)

Retracted: “Correlation between ER, PR, P53, Ki67 expression, and high-risk HPV infection in patients with different levels of cervical intraepithelial neoplasia”
Published: (2023-02-01)

Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy.
by: Sasagu Kurozumi, et al.
Published: (2019-01-01)

The Effect of Tumor Markers ER, Her2, and Ki67 on Long-Term and Short-Term Survival of Women with Breast Cancer Using Bayesian Cure Model
by: Morteza Mohammadzadeh, et al.
Published: (2019-12-01)

Ki-67 and CK-19 are predictors of locoregional recurrence in papillary thyroid carcinoma
by: Aline de Oliveira Ribeiro Viana, et al.
Published: (2020-06-01)

Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience
by: Michela Palleschi, et al.
Published: (2020-08-01)

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
by: Mengyuan Cai, et al.
Published: (2023-07-01)

Expression of HER2/neu and Ki-67 in Urothelial Carcinoma and their Relation to Clinicopathological Data: An Egyptian Study
by: Badawia B Ibrahim, et al.
Published: (2021-03-01)

Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer
by: M.C. Kriegmair, et al.
Published: (2018-04-01)